Metastatic suppressor CD44 is related with oxidative stress in breast cancer cell lines

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1481-1489

  Echiburu Chau C ^a   Roy, D ^b   Calaf, Gloria M ^a,c  

^a UNIVERSIDAD DE TARAPACÁ   (Chile)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Breast cancer; CD44; Metastasis; Oxidative stress

Indexed keywords

CATHEPSIN D; CAVEOLIN 1; COMPLEMENTARY DNA; HERMES ANTIGEN; MANGANESE SUPEROXIDE DISMUTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL STRESS; CONTROLLED STUDY; DNA MICROARRAY; FAR WESTERN BLOTTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; NEOPLASM METASTASIS; OXIDATIVE STRESS;

EID: 80054804481     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1154     Document Type: Article

References (66)

1. D'Autreaux B and Toledano MB: ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813-824, 2007. (Pubitemid 47462134)
2. Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794, 2007. (Pubitemid 46340350)
3. Ushio-Fukai M and Nakamura Y: Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 266: 37-52, 2008. (Pubitemid 351753035)
4. Clerkin JS, Naughton R, Quiney C and Cotter TG: Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 266: 30-36, 2008.
5. Giles GI: The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 12: 4427-4443, 2006.
6. Kheradmand F, Werner E, Tremble P, Symons M and Werb Z: Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 280: 898-902, 1998. (Pubitemid 28215599)
7. Ben Mahdi MH, Andrieu V and Pasquier C: Focal adhesion kinase regulation by oxidative stress in different cell types. IUBMB Life 50: 291-299, 2000. (Pubitemid 32289087)
8. Nabeshima K, Inoue T, Shimao Y and Sameshima T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-264, 2002. (Pubitemid 34587810)
9. Nelson KK and Melendez JA: Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37: 768-784, 2004. (Pubitemid 39078549)
10. Li H, Kantoff PW, Giovannucci E, et al.: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65: 2498-2504, 2005. (Pubitemid 40490163)
11. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J and Leffall LD: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 11: 481-483, 2005. (Pubitemid 40685969)
12. Friedl P and Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362-374, 2003. (Pubitemid 37328856)
13. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904, 2006.
14. Oxmann D, Held-Feindt J, Stark AM, Hattermann K, Yoneda T and Mentlein R: Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 27: 3567-3575, 2008. (Pubitemid 351793804)
15. Calaf GM and Hei TK: Establishment of a radiation and estrogen-induced breast cancer model. Carcinogenesis 21: 769-776, 2000. (Pubitemid 30214035)
16. Calaf GM, Emenaker NJ and Hei TK: Effect of retinol on radiation- and estrogen-induced neoplastic transformation of human breast epithelial cells. Oncol Rep 13: 1017-1027, 2005
17. Echiburú-Chau C, Roy D and Calaf GM: Deleterious MnSOD signals lead to abnormal breast cell proliferation by radiation and estrogen exposure. Int J Oncol 38: 1703-1711, 2011.
18. Ray G, Batra S, Shukla NK, et al.: Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 59: 163-170, 2000. (Pubitemid 30216139)
19. Connor KM, Hempel N, Nelson KK, et al.: Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res 67: 10260-10267, 2007. (Pubitemid 350070799)
20. Li N, Oberley TD, Oberley LW and Zhong W: Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35: 221-233, 1998. (Pubitemid 28211296)
21. Cullen JJ, Weydert C, Hinkhouse MM, et al.: The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 63: 1297-1303, 2003. (Pubitemid 36348708)
22. Li JJ, Oberley LW, St Clair DK, Ridnour LA and Oberley TD: Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 10: 1989-2000, 1995.
23. Hyoudou K, Nishikawa M, Kobayashi Y, Ikemura M, Yamashita F and Hashida M: SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clin Exp Metastasis 25: 531-536, 2008.
24. Malafa M, Margenthaler J, Webb B, Neitzel L and Christophersen M: MnSOD expression is increased in metastatic gastric cancer. J Surg Res 88: 130-134, 2000. (Pubitemid 30085842)
25. Toh Y, Kuninaka S, Oshiro T, et al.: Overexpression of manganese superoxide dismutase mRNA may correlate with aggressiveness in gastric and colorectal adenocarcinomas. Int J Oncol 17: 107-112, 2000.
26. Punnonen K, Ahotupa M, Asaishi K, Hyoty M, Kudo R and Punnonen R: Antioxidant enzyme activities and oxidative stress in human breast cancer. J Cancer Res Clin Oncol 120: 374-377, 1994. (Pubitemid 24101438)
27. Zhao H, Tanaka T, Mitlitski V, Heeter J, Balazs EA and Darzynkiewicz Z: Protective effect of hyaluronate on oxidative DNA damage in WI-38 and A549 cells. Int J Oncol 32: 1159-1167, 2008.
28. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J and Schroeder JA: CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 65: 6755-6763, 2005. (Pubitemid 41060713)
29. Nonaka Y, Iwagaki H, Kimura T, Fuchimoto S and Orita K: Effect of reactive oxygen intermediates on the in vitro invasive capacity of tumor cells and liver metastasis in mice. Int J Cancer 54: 983-986, 1993. (Pubitemid 23267473)
30. Kahlos K, Soini Y, Paakko P, Saily M, Linnainmaa K and Kinnula VL: Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int J Cancer 88: 37-43, 2000.
31. Nelson KK, Ranganathan AC, Mansouri J, et al.: Elevated sod2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res 9: 424-432, 2003. (Pubitemid 36109760)
32. Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
33. Gupta A, Butts B, Kwei KA, et al.: Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression. Cancer Lett 173: 115-125, 2001. (Pubitemid 32971928)
34. Nishikawa M, Tamada A, Kumai H, Yamashita F and Hashida M: Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer 99: 474-479, 2002. (Pubitemid 34495865)
35. Kinnula VL and Crapo JD: Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 36: 718-744, 2004. (Pubitemid 38264416)
36. Hnasko R and Lisanti MP: The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3: 445-464, 2003.
37. Koleske AJ, Baltimore D and Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92: 1381-1385, 1995.
38. Bender FC, Reymond MA, Bron C and Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60: 5870-5878, 2000.
39. Kato K, Hida Y, Miyamoto M, et al.: Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929-933, 2002. (Pubitemid 34150846)
40. Mouraviev V, Li L, Tahir SA, et al.: The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168: 1589-1596, 2002. (Pubitemid 35034195)
41. Lavie Y, Fiucci G and Liscovitch M: Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383, 1998. (Pubitemid 28557607)
42. Hayashi K, Matsuda S, Machida K, et al.: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001. (Pubitemid 32685805)
43. Li T, Sotgia F, Vuolo MA, et al.: Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168: 1998-2013, 2006. (Pubitemid 43825319)
44. Bonuccelli G, Casimiro MC, Sotgia F, et al.: Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol 174: 1650-1662, 2009.
45. Carver LA and Schnitzer JE: Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 3: 571-581, 2003. (Pubitemid 37328829)
46. Yang G, Truong LD, Timme TL, et al.: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998. (Pubitemid 28369170)
47. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC and Mellon JK: Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58: 811-814, 2001.
48. Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG and Nesland JM: Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42: 546-554, 2003. (Pubitemid 36688148)
49. Diaz LK, Zhou X, Wright ET, et al.: CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11: 3309-3314, 2005. (Pubitemid 40627880)
50. Gong Y, Sun X, Huo L, Wiley EL and Rao MS: Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast. Histopathology 46: 24-30, 2005. (Pubitemid 40193694)
51. Wu GS, Saftig P, Peters C and El-Deiry WS: Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16: 2177-2183, 1998. (Pubitemid 28220647)
52. Brown NS and Bicknell R: Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3: 323-327, 2001. (Pubitemid 32851163)
53. Suzuki K, Deyashiki Y, Nishioka J, et al.: Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem 262: 611-616, 1987. (Pubitemid 17005226)
54. Silverman GA, Bird PI, Carrell RW, et al.: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293-33296, 2001.
55. Fabre-Guillevin E, Malo M, Cartier-Michaud A, et al.: PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Res 10: R100, 2008.
56. Wilkins-Port CE, Higgins CE, Freytag J, Higgins SP, Carlson JA and Higgins PJ: PAI-1 is a critical upstream regulator of the TGF-beta1/EGF-induced invasive phenotype in mutant p53 human cutaneous squamous cell carcinoma. J Biomed Biotechnol 2007: 85208, 2007.
57. Chorostowska-Wynimko J, Skrzypczak-Jankun E and Jankun J: Plasminogen activator inhibitor type-1: Its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med 13: 759-766, 2004.
58. Samarakoon R, Higgins CE, Higgins SP, Kutz SM and Higgins PJ: Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. J Cell Physiol 204: 236-246, 2005. (Pubitemid 40776827)
59. Wang Z, Sosne G and Kurpakus-Wheater M: Plasminogen activator inhibitor-1 (PAI-1) stimulates human corneal epithelial cell adhesion and migration in vitro. Exp Eye Res 80: 1-8, 2005. (Pubitemid 40126508)
60. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539, 2004.
61. Jaracz S, Chen J, Kuznetsova LV and Ojima I: Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 13: 5043-5054, 2005. (Pubitemid 41039965)
62. Toole BP: Hyaluronan in morphogenesis. J Intern Med 242: 35-40, 1997.
63. Liu CM, Chang CH, Yu CH, Hsu CC and Huang LL: Hyaluronan substratum induces multidrug resistance in human mesenchymal stem cells via CD44 signaling. Cell Tissue Res 336: 465-475, 2009.
64. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H and Miyasaka M: Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 278: 32259-32265, 2003. (Pubitemid 37048419)
65. Soltes L, Kogan G, Stankovska M, et al.: Degradation of high-molar-mass hyaluronan and characterization of fragments. Biomacromolecules 8: 2697-2705, 2007. (Pubitemid 47516918)
66. Balaza EA, Davies JV, Phillips GO and Young MD: Transient intermediates in the radiolysis of hyaluronic acid. Radiat Res 31: 243-255, 1967.